三聚氰胺胶体金免疫层析试纸条的研制

通过胶体金免疫层析技术建立一种特异、便捷、快速的三聚氰胺抗原检测方法,对奶制品及饲料中的三聚氰胺残留水平监测提供参考。用柠檬酸三钠还原法制备的胶体金,标记纯化的三聚氰胺单克隆抗体,喷于试纸的金标垫。将MEL-OVA(三聚氰胺和卵清白蛋白的偶练物)和纯化的羊抗鼠IgG分别喷于试纸的T(检测线)处和C(质控线)处,通过挑选试纸条材料和调试工艺参数,并最终组装成试纸条。结果显示,制备的试纸监测体系方法检出限为50 g/L。试纸条对牛奶、奶粉和饲料中的三聚氰胺残留的检出限分别为100 g/L、100 ng/g和200 ng/g。将该法与LC-MS/MS法对比检测牛奶、奶粉和饲料样品,在试纸条检测范围内,与LC-MS/MS法检测结果一致性好,从而验证了该方法的有效性。制备的三聚氰胺胶体金检测试纸在常温干燥环境下至少可保质6个月,能够检测出三聚氰胺含量大于50 g/L的样品,适用于现场实际样品三聚氰胺残留水平监测,具有良好的应用前景。     

一种从抗狂犬病病毒噬菌体抗体库中筛选和验证中和抗体的方法

目的建立一种从噬菌体库抗体库中高效筛选和验证抗狂犬病病毒中和抗体的方法。方法①定性分析:从经过灭活的CVS-11筛选噬菌体抗体库中挑取单克隆于96孔板中培养,制备噬菌体抗体,取培养上清进行快速荧光灶抑制试验(rapid fluorescent focus inhibition test, RFFIT),选择可明显抑制病毒感染的克隆测序,获得具有中和活性的抗体可变区序列;②定量分析:挑选有中和活性的克隆,重新制备噬菌体抗体颗粒,纯化后进行RFFIT分析;扩增抗体可变区基因,构建真核瞬时表达质粒。瞬转HEK-293 EBNA1细胞,培养上清经Mabselect SuRe亲和纯化后测定抗体比活。结果定性分析获得的噬菌体抗体颗粒与全分子抗体体外中和活性显著相关;剔除低活性序列后,活性高于0.5 IU/mL的噬菌体抗体颗粒与其全分子抗体体外中和活性之间无显著相关;所有纯化后噬菌体抗体颗粒活性>0.5 IU/mL的序列其全分子抗体体外中和活性均>500 IU/mg。结论构建了一种从抗狂犬病病毒噬菌体库中高效筛选、验证中和抗体的方法。     

RFFIT、FAVN、ELISA及狂犬病中和抗体检测试剂盒对狂犬病抗体检测的比较研究

为了比较RFFIT、FAVN、ELISA及狂犬病中和抗体检测试剂盒(RVNA Kit)等四种方法对狂犬病抗体的检测效果,对65份狂犬病疫苗免疫前、免疫后临床血清样本,分别使用RFFIT、FAVN、ELISA及RVNA Kit方法对狂犬病病毒特异性抗体进行测定,并对检测结果的阳性符合率、相关性及重复性进行分析。检测结果显示,RFFIT、FAVN及RVNA kit的阳性符合率为100%,三种方法与ELISA试剂盒的阳性符合率为95.38%,对0.5IU/mL~10IU/mL的血清样本进行阳性符合率分析显示,四种方法的阳性符合率为100%;相关性研究结果表明,RFFIT、FAVN及RVNA Kit之间任意两种方法检测结果的相关系数均超过0.97,但ELISA与其他三种方法检测结果的相关系数均低于0.86;同一份样品的重复性检验结果显示,RVNA Kit和ELISA比RFFIT和FAVN具有更好的重复性,而RVNA Kit的重复性最好,其变异系数仅6%。研究结果表明,RFFIT、FAVN及RVNA Kit等三种方法可通用于血清中抗狂犬病病毒中和抗体的检测,而ELISA检测结果与中和抗体效价有一定差距,但在经过优化、校验后ELISA也可以在有效范围内用于狂犬病抗体的检测。     

狂犬病病毒M蛋白在杆状病毒中的表达、纯化及多克隆抗体的制备

为表达狂犬病病毒(Rabies Virus,RV)基质蛋白(M)蛋白,进而制备多克隆抗体。本研究以狂犬病病毒BD06株RNA为模版,通过RT-PCR扩增M蛋白基因全序列,将其插入质粒pFastbac I中,获取的重组质粒pFastbac I-M,经酶切鉴定后,转化到DH10Bac E.coli感受态中,以获取重组穿梭质粒Bacmid-M。用lipofectamine2000介导Bacmid-M转染Sf9细胞获取重组杆状病毒AcMNPV-M。用抗His标签的单体、犬抗RV阳性血清及兔抗RV阳性血清通过Western-Blot鉴定重组蛋白的表达及其反应原性。用镍离子亲和层析柱纯化重组蛋白,并免疫新西兰大耳白兔制备多克隆抗体,用Western-Blot和FAVN试验鉴定多克隆抗体的反应原性及其病毒中和效价。结果表明:(1)利用杆状病毒表达系统成功的表达了大小约为25kD的重组M蛋白;(2)重组M蛋白具有良好的免疫原性和反应原性;(3)制备的多克隆抗体与狂犬病病毒BD06、SRV 9、CVS-24、ERA、PV 2061及aG株的M蛋白均能发生特异性反应,但其无病毒中和能力。本研究完成了重组M蛋白的表达、纯化并制备了其多克隆抗体,为进一步研究M蛋白的生物学功能奠定了物质基础。     

鲤疱疹病毒Ⅱ型抗体胶体金检测试纸条的制备和分析

【背景】由鲤疱疹病毒Ⅱ型(cyprinid herpesvirus-2, CyHV-2)引起的疱疹病毒性造血坏死病在鲫和金鱼中的暴发给水产养殖业造成了巨大的经济损失。【目的】开发一种快速、现场检测鲫是否感染过CyHV-2和监测鲫CyHV-2IgM抗体水平的胶体金检测试纸条。【方法】将CyHV-2与胶体金结合作为金标抗原、Protein A作为检测线、兔源rORF66多克隆抗体进行划线作为质控线，分析胶体金试纸条最佳制备及组装条件，确定胶体金标记最适pH、金标抗原最适浓度，以及检测线(test line, T线)、质控线(control line, C线)最适划线浓度等。【结果】本研究制备的CyHV-2抗体胶体金试纸条可以使用全血测试，与常见的其他鱼类抗体血清无交叉反应，如草鱼呼肠孤病毒抗体阳性血清、鳜虹彩病毒抗体阳性血清等。试纸条最低限度可以检测到1:100稀释的阳性血清抗体，由试纸条检测线的深浅可以初步判断鱼体中抗体水平。试纸条通过对10条鲫鱼血清样品检测并和金鱼造血器官坏死病毒检测方法(GB/T 36194—2018)进行Kappa分析，Kappa值为0.80，表明二者有较高的符合...     

甲胎蛋白和癌胚抗原的胶体金免疫层析同步检测

目的:探讨建立一种同时快速检测甲胎蛋白(AFP)和癌胚抗原(CEA)两种肿瘤标志物的方法.方法:用胶体金分别标记鼠抗AFP单克隆抗体和鼠抗CEA单克隆抗体,喷于胶金垫上.与之配对的抗体喷在硝酸纤维素膜(NC膜)上分别做检测线T2和T1,兔抗鼠二抗喷在NC膜上做质控线,利用免疫层析技术进行检测.结果:采用Frens方法制备的胶体金粒径在20nm,紫外可见吸收峰在521 nm处,金标抗体的最适pH在9.0,最适抗体量为200μl,胶体金标记2.4μg抗体.测试结果表明同时检测AFP和CEA的试纸条灵敏度分别为20 ng.mL-1和5 ng.mL-1,检测时间仅需10min,与PSA、CA125、CA15-3、Ferritin、Human Albumin等没有交叉反应,稳定性好.结论:应用胶体金免疫层析技术,实现了AFP和CEA的同步检测.     

人肺炎链球菌快速检测胶体金试纸的研制

[目的]研制一种快速检测人肺炎链球菌(S. pneumoniae)的免疫胶体金层析试纸。[方法]对肺炎链球菌表面蛋白A(pneumococcal surface protein A,PspA)基因序列(Gen Bank:U89711)作生物信息学分析,选取抗原表位强、种内同源性高的片段克隆表达纯化重组蛋白rPspA,并免疫BALB/c小鼠制备单克隆抗体;以双抗夹心法制备胶体金免疫层析试纸,并对其特异性、灵敏度以及稳定性进行验证分析。[结果]制备的胶体金试纸对rPspA最低检测限达到0. 1pg/m L,可在15min内完成对肺炎链球菌的检测,与其他10种重要呼吸道病原菌无交叉反应;试纸条在25℃条件下保存6个月仍具有良好的重复性和稳定性。[结论]PspA蛋白具有高度的表面暴露性和较强的抗原性,可作为Sp的检测标志物,以其抗体为基础制备的胶体金免疫层析试纸,适用于Sp菌感染的临床快速检测。     

高效价冻干人用狂犬病疫苗暴露后免疫程序的研究

初步确定高效价冻干人用狂犬病疫苗（6．0IU／剂）暴露后免疫程序。制备高效价的冻干人用狂犬病疫苗（6．0IU／剂）,以狂犬病街毒CNX8601和BD06分别攻击小鼠和比格犬的咬肌,接种不同效价的狂犬病疫苗,以RFFIT法检测中和抗体,根据动物死亡情况,计算暴露后疫苗保护率,对不同效价的疫苗进行中和抗体测定和保护率统计分析。在以小鼠为实验动物的疫苗保护率研究中,冻干人用狂犬病疫苗（3．1IU／剂）0／3／7／14／28免疫程序的保护率为40．6％,高效价的冻干人用狂犬病疫苗（6．0IU／剂）0／3／14免疫程序的保护率为56．2％,中和抗体比较,P〈0．05,2组间有显著性差异;在以比格犬为实验动物的保护效果研究中,冻干人用狂犬病疫苗的保护率（3．1IU／剂）为70％;高效价的冻干人用狂犬病疫苗（6．0IU／剂）的保护率为80％,中和抗体的比较,P〉0．05,没有显著性差异。高效价冻干人用狂犬病疫苗暴露后免疫程序可初步确定为0、3、14d免疫。     

一种超高灵敏的埃博拉病毒胶体碳侧流免疫层析检测方法的建立

埃博拉出血热 (Ebola hemorrhagic fever, EHF) 由于其高感染性和高致死率特点,快速鉴别诊断并实施隔离是最有效的防止疫情扩散的措施。文中建立了一种可以快速、高灵敏筛查埃博拉病毒 (Ebola virus,EBOV)感染的现场检测技术,用碳纳米颗粒标记抗EBOV基质蛋白VP40兔多克隆抗体,组装成一种可在15 min内检测埃博拉病毒的胶体碳侧流免疫层析试纸条。将标记胶体碳颗粒的兔多抗喷涂于玻璃纤维素膜上制备碳标垫;以1 mg/mL的抗VP40单克隆抗体 (McAb,4B7F9) 和羊抗兔IgG,按照2 μL/cm的包被量印迹于硝酸纤维膜上,分别作为检测线与质控线,组装试纸条。该试纸条能够特异地检测EBOV重组VP40蛋白、EBOV病毒样颗粒(Virus-like particles,VLP) 和灭活EBOV,而与马尔堡病毒样颗粒 (MARV-VLP)、流感病毒A/PR/8 (IAV/PR/8)、黄热病毒 (YFV-17D)、登革热病毒2型 (DEN2) 无交叉反应,显示良好的特异性,对1 500份阴性血清进行检测,假阳性率为1.3‰,仅为WHO授权ReEBOV?胶体金试纸的1/100;该胶体碳试纸条检测灭活EBOV的最低检出限为100 ng/mL (相当于106 copies/mL),远优于ReEBOV?胶体金试纸条检出限 (10 μg/mL,相当于108 copies /mL)。热稳定性评价显示试纸条可在室温稳定保存1年以上。文中建立的EBOV胶体碳免疫层析试纸条能够快速、超高灵敏、特异地检测EBOV,为现场快速筛查EBOV感染提供一种新方法。     

表达狂犬病毒糖蛋白抗原的重组犬2型腺病毒的构建及鉴定

为研制一种预防犬科动物狂犬病的新型疫苗,将含有狂犬病毒ERA株糖蛋白基因(Rabies glycoprotein,Rgp)表达盒的穿梭质粒pVAXΔE3Rgp中的Rgp表达盒克隆入犬2型腺病毒(Canine adenovirus type2,CAV2)骨架质粒pPoly2-CAV2中,获得重组质粒pPoly2-CAV2-ΔE3-Rgp,释放其基因组,转染MDCK细胞系,获得E3缺失区(Deletion of early protein3,ΔE3)含有Rgp表达盒的重组病毒CAV2-ΔE3-Rgp。该重组病毒能在MDCK细胞上产生典型的腺病毒细胞病变。通过酶切、PCR、基因测序,表明该重组病毒含有完整的Rgp表达盒。通过RT-PCR、Western blot等检测,表明该重组病毒能够表达Rgp抗原。用该重组病毒免疫犬,3次免疫后,可以诱导犬产生特异的抗CAV2HI抗体,其效价超过1∶256和抗狂犬病病毒(Rabies virus,RV)中和抗体,其效价超过0.50IU/mL。试验结果表明,获得的重组病毒免疫犬后,能够产生抗狂犬病毒和腺病毒的高效价保护性抗体,是一种有潜力的犬科动物狂犬病毒腺病毒二联疫苗候选株。     

双抗体夹心ELISA与NIH法在狂犬病疫苗抗原检测中的比较

通过用单克隆抗体制备双抗体夹心ELISA,快速检测狂犬病疫苗中狂犬病毒糖蛋白(G)的含量,将狂犬病疫 苗的检定时间由28天缩短至2个工作日,以此缩短疫苗库存待检时间,提高疫苗的生产和销售效率,并最终替代 NIH动物法。将待检的狂犬病疫苗样品在同一性别12～14g昆明鼠体内作效力检定试验(NIH),同时用双抗体夹 心ELISA检测狂犬病疫苗中狂犬病毒G蛋白含量,用Microsoft Office Excel做出标准品和各样品疫苗的线性关 系图并计算出疫苗效力值E-NIH。结果用双抗体夹心ELISA所得的E-NIH与对应的小鼠效力试验所得结果M- NIH之间呈正相关性;同一批狂犬病疫苗分次测得E-NIH值在2．41～5．85之间,而相应的M-NIH值在5．11～ 10．19之间。从而得出E-NIH与相应的M-NIH之间存在明显的线性关系;与NIH法比较,ELISA具有重复性好、 成本低、快速等优点;用双抗体夹心ELISA替代小鼠效力试验是可能并可行的。     

Proteomic profiles of mouse neuro N2a cells infected with variant virulence of rabies viruses

We characterized the proteomes of murine N2a cells following infection with three rabies virus (RV) strains, characterized by distinct virulence phenotypes (i.e., virulent BD06, fixed CVS-11, and attenuated SRV9 strains), and identified 35 changes to protein expression using two-dimensional gel electrophoresis in whole-cell lysates. The annotated functions of these proteins are involved in various cytoskeletal, signal transduction, stress response, and metabolic processes. Specifically, a-enolase, prx-4, vimentin, cytokine-induced apoptosis inhibitor 1 (CIAPIN1) and prx-6 were significantly up-regulated, whereas Trx like-1 and galectin-1 were down-regulated following infection of N2a cells with all three rabies virus strains. However, comparing expressions of all 35 proteins affected between BD06-, CVS-11-, and SRV9-infected cells, specific changes in expression were also observed. The up-regulation of vimentin, CIAPIN1, prx-4, and 14-3-3 theta/delta, and downregulation of NDPK-B and HSP-1 with CVS and SRV9 infection were ≥ 2 times greater than with BD06. Meanwhile, Zfp12 protein, splicing factor, and arginine/serine-rich 1 were unaltered in the cells infected with BD06 and CVS- 11, but were up-regulated in the group infected with SRV9. The proteomic alterations described here may suggest that these changes to protein expression correlate with the rabies virus' adaptability and virulence in N2a cells, and hence provides new clues as to the response of N2a host cells to rabies virus infections, and may also aid in uncovering new pathways in these cells that are involved in rabies infections. Further characterization of the functions of the affected proteins may contribute to our understanding of the mechanisms of RV infection and pathogenesis.     

The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays

The effect that the relatedness of the viral seed strain used to produce rabies vaccines has to the strain of challenge virus used to measure rabies virus neutralizing antibodies after vaccination was evaluated. Serum samples from 173 subjects vaccinated with either purified Vero cell rabies vaccine (PVRV), produced from the Pittman Moore (PM) seed strain of rabies virus, or purified chick embryo cell rabies vaccine (PCECV), produced from the Flury low egg passage (Flury-LEP) seed strain of rabies virus, were tested in parallel assays by RFFIT using a homologous and a heterologous testing system. In the homologous system, CVS-11 was used as the challenge virus in the assay to evaluate the humoral immune response in subjects vaccinated with PVRV and Flury-LEP was used for subjects vaccinated with PCECV. In the heterologous system, CVS-11 was used as the challenge virus in the assay to evaluate subjects vaccinated with PCECV and Flury-LEP was used for subjects vaccinated with PVRV. Although the difference in G protein homology between the CVS-11 and Flury-LEP rabies virus strains has been reported to be only 5.8%, the use of a homologous testing system resulted in approximately 30% higher titers for nearly two-thirds of the samples from both vaccine groups compared to a heterologous testing system. The evaluation of equivalence of the immune response after vaccination with the two different vaccines was dependent upon the type of testing system, homologous or heterologous, used to evaluate the level of rabies virus neutralizing antibodies. Equivalence between the vaccines was achieved when a homologous testing system was used but not when a heterologous testing system was used. The results of this study indicate that the strain of virus used in the biological assays to measure the level of rabies virus neutralizing antibodies after vaccination could profoundly influence the evaluation of rabies vaccines.     

Rabies virus ocular disease: T-cell-dependent protection is under the control of signaling by the p55 tumor necrosis factor alpha receptor, p55TNFR

Following brain infection, the Challenge Virus Standard strain of rabies virus infects the retina. Rabies virus ocular infection induces the infiltration of neutrophils and predominantly T cells into the eye. The role of tumor necrosis factor alpha (TNF-alpha)-lymphotoxin signaling in the control of rabies virus ocular infection and inflammatory cell infiltration was assessed using mice lacking the p55 TNF-alpha receptor (p55TNFR(-/-) mice). The incidence of ocular disease and the intensity of retinal infection were greater in p55TNFR(-/-) mice than in C57BL/6 mice: the aggravation correlated with less neutrophil and T-cell infiltration. This indicates that cellular infiltration is under the control of the p55 TNF-alpha receptor and suggests that inflammatory cells may protect the eye against rabies virus ocular infection. The role of T cells following rabies virus ocular disease was assessed by comparison of rabies virus infection in nude mice with their normal counterparts. Indeed, the incidence and severity of the rabies virus ocular disease were higher in athymic nude mice than in BALB/c mice, indicating that T lymphocytes are protective during rabies virus ocular infection. Moreover, few T cells and neutrophils underwent apoptosis in rabies virus-infected retina. Altogether, these data suggest that T lymphocytes and neutrophils are able to enter the eye, escape the immune privilege status, and limit rabies virus ocular disease. In conclusion, rabies virus-mediated eye disease provides a new model for studying mechanisms regulating immune privilege during viral infection.     

Oral vaccination of captive arctic foxes with lyophilized SAG2 rabies vaccine

Arctic foxes (Alopex lagopus) were immunized with lyophilized SAG2 oral rabies vaccine. The effectiveness of this vaccine was determined by serologic response and survival to challenge by rabies virus isolated from a red fox from Alaska (USA). No vaccine virus was found in saliva 1-72 hr after ingestion. At 2 wk after vaccination, all foxes had seroconverted, with rabies virus neutralizing antibody levels of 0.2-3.1 IU ml(-1). All vaccinated foxes survived to week 17 after challenge, and hippocampus, pons, and cerebellum were free of rabies virus as determined by direct immunofluorescence testing after death. One of four nonvaccinated foxes survived challenge and was free of rabies virus in neural tissue, and no rabies virus neutralizing antibody was detected in blood. Our results suggest that the lyophilized SAG2 oral rabies vaccine could be effective in arctic and subarctic regions, where freezing air and ground temperatures probably would not reduce its immunogenicity.     

Experience with antirabies vaccination of foxes using the oral route coordinated among several European countries and perspectives on the use of recombinant vaccinia-rabies virus

Campaigns of fox vaccination against rabies were carried out in Belgium, grand-duchy of Luxembourg and France in September 1986, June and September 1987. The SAD B19 attenuated strain of rabies virus, contained in baits (Tübingen baits) was used as vaccine. Baits were distributed at a range density of 11 to 15 baits per km2. First results are very encouraging. A recombinant vaccinia virus harbouring the rabies virus glycoprotein gene has been developed. This recombinant virus can be given to the fox by the oral route and protects it against rabies virus challenge; it is also innocuous for the fox and other non-target European species. A first trial of fox vaccination against rabies using this recombinant vaccinia-rabies virus has been carried out in Belgium, on a military domain, in October 1987.     

Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity

The pathogenicity of individual rabies virus strains appears to correlate inversely with the extent of apoptotic cell death they induce and with the expression of rabies virus glycoprotein, a major inducer of an antiviral immune response. To determine whether the induction of apoptosis by rabies virus contributes to a decreased pathogenicity by stimulating antiviral immunity, we have analyzed these parameters in tissue cultures and in mice infected with a recombinant rabies virus construct that expresses the proapoptotic protein cytochrome c. The extent of apoptosis was strongly increased in primary neuron cultures infected with the recombinant virus carrying the active cytochrome c gene [SPBN-Cyto c(+)], compared with cells infected with the recombinant virus containing the inactive cytochrome c gene [SPBN-Cyto c(-)]. Mortality in mice infected intranasally with SPBN-Cyto c(+) was substantially lower than in SPBN-Cyto c(-)-infected mice. Furthermore, virus-neutralizing antibody (VNA) titers were significantly higher in mice immunized with SPBN-Cyto c(+) at the same dose. The VNA titers induced by these recombinant viruses paralleled their protective activities against a lethal rabies virus challenge infection, with SPBN-Cyto c(+) revealing an effective dose 20 times lower than that of SPBN-Cyto c(-). The strong increase in immunogenicity, coupled with the marked reduction in pathogenicity, identifies the SPBN-Cyto c(+) construct as a candidate for a live rabies virus vaccine.     

Characterization of saturable binding sites for rabies virus.

A specific, saturable receptor for rabies virus was analyzed on cultured cells of neural or non-neural origin. Viral attachment kinetics were enhanced by DEAE-dextran, an effect which in turn enhanced the apparent infectivity of the virus inoculum. Under optimized conditions, the attachment of metabolically labeled ERA strain rabies virus obeyed the laws of mass action, whereby the amount of virus bound to cells varied proportionally with the concentration of cells or virus. Attachment was sensitive to changes of temperature and pH, did not require divalent cations such as Mg2+ or Ca2+, and occurred despite prior treatment of cells with proteolytic or sialic acid-specific enzymes. Saturation of the cell surface with rabies virus could be accomplished with 3 X 10(3) to 15 X 10(3) attached virions per cell. Competition for the rabies receptor occurred with rabies nonpathogenic variant virus, RV194 -2, and vesicular stomatitis virus. Reovirus type 3, another neurotropic virus, failed to inhibit rabies virus binding, and West Nile virus only slightly inhibited rabies virus binding, suggesting independent cellular receptors were recognized by these viruses. Isolated rabies virus glycoprotein failed to compete in an equivalent manner. However, solubilization of BHK-21 cells with octylglucoside yielded a chloroform-methanol-soluble extract which blocked rabies virus attachment. The binding inhibition activity of this extract was resistant to proteases but could be destroyed by phospholipases and neuraminidase, suggesting a phospholipid or glycolipid component at the receptor site. These data provide evidence for a rhabdovirus-common mechanism for cellular attachment to cells in culture.